MITRA N.V. Mithra Pharmaceuticals S.A.

Mithra Reports Full Year 2019 Financial Results

Mithra Reports Full Year 2019 Financial Results

  • Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle®
  • Anticipated future licensing milestones for Estelle® of EUR 322 million (out of a total of EUR 486 million)
  • Net loss significantly reduced to EUR 26.6 million (EUR 89.7 million in June 2019) thanks to successful earnout renegotiation and landmark deal with Mayne Pharma for Estelle®
  • Strengthening of book equity to EUR 163.3 million thanks to earnout renegotiation
  • Continued good cash management with comfortable level of cash at year-end
  • Key milestones achieved for environmental-friendly E4-based portfolio pipeline, with successful launch of Phase III study of Donesta® in menopause and regulatory submission of Estelle® in Europe
  • Valuation of business entity for clinical development projects based on E4 in 2020



Liege, Belgium, 09 March 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2019, prepared in accordance with IFRS.

Mithra will host a conference call and live webcast today (March 9, 2020) at 15:00 CET/9:00 EST. The live webcast can be accessed on the Mithra website or 

Attachment

EN
09/03/2020

Underlying

MITRAN.V. Mithra Pharmaceuticals S.A.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on N.V. Mithra Pharmaceuticals S.A.

Guy Sips ... (+4)
  • Guy Sips
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi
AGFB AGFA-GEVAERT NV
MITRA N.V. MITHRA PHARMACEUTICALS S.A.
06/11/24 June 11, 2024 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
XIOR XIOR STUDENT HOUSING N.V.
FLOB FLORIDIENNE S.A.
MONT MONTEA SCA
MITRA N.V. MITHRA PHARMACEUTICALS S.A.
ATEB ATENOR S.A.
DSFIR KONINKLIJKE DSM N.V.
06/04/24 June 4, 2024 1 EN
 PRESS RELEASE
Free
MITRA N.V. Mithra Pha...

Mithra postpones its annual general meeting

Mithra postpones its annual general meeting Liege, Belgium, 28 May 2024 – 15:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that in the context of the monetization process and the uncertainties related thereto, Mithra postpones its Annual General Shareholders’ Meeting, , to a later date to be determined.  Background Information:  Mithra announced the launch of a comprehensive monetization process, exploring potential sales of selected assets, notably Estetra SRL, and potentially the entire business. Additionally, Mithra announced the en...

May 28, 2024 1 EN
Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
PNL POSTNL NV
MITRA N.V. MITHRA PHARMACEUTICALS S.A.
TWEKA TKH GROUP N.V. CERT
UMI UMICORE
05/06/24 May 6, 2024 1 EN
 PRESS RELEASE
Free
MITRA N.V. Mithra Pha...

Mithra enters into exclusive negotiations with Gedeon Richter and secu...

Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process Liege, Belgium, 3 May 2024 – 17:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that, after diligent evaluation of , Mithra has selected the offer submitted by Gedeon Richter, which relates to Estetra SRL, Neuralis SA and specific assets held by Mithra R&D SA related to the E4 platform, as a basis for further negotiations and decided to grant exclusivity to Gedeon Richter for the purpose of such negotiation...

May 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch